Last reviewed · How we verify
Activated allogeneic white blood cells
Activated allogeneic white blood cells stimulate the immune system to fight infections and diseases.
Activated allogeneic white blood cells stimulate the immune system to fight infections and diseases. Used for Treatment of diabetic foot ulcers.
At a glance
| Generic name | Activated allogeneic white blood cells |
|---|---|
| Also known as | CureXcell |
| Sponsor | Macrocure Ltd. |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This is achieved through the activation of white blood cells, which are then administered to the patient to enhance their immune response. The exact mechanism of action may vary depending on the specific disease being targeted.
Approved indications
- Treatment of diabetic foot ulcers
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (EARLY_PHASE1)
- Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma (PHASE2)
- The Use of CureXcellTM in a Community Setting for the Treatment of Hard to Heal Wounds
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Activated allogeneic white blood cells CI brief — competitive landscape report
- Activated allogeneic white blood cells updates RSS · CI watch RSS
- Macrocure Ltd. portfolio CI